APA (7th ed.) Citation

Horinouchi, H., Cho, B., Camidge, D., Goto, K., Tomasini, P., Li, Y., . . . Goldman, J. (2025). Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Annals of Oncology, 36(5), 583. https://doi.org/10.1016/j.annonc.2025.01.001

Chicago Style (17th ed.) Citation

Horinouchi, H., et al. "Results from a Phase Ib Study of Telisotuzumab Vedotin in Combination with Osimertinib in Patients with C-Met Protein-overexpressing, EGFR-mutated Locally Advanced/metastatic Non-small-cell Lung Cancer (NSCLC) After Progression on Prior Osimertinib." Annals of Oncology 36, no. 5 (2025): 583. https://doi.org/10.1016/j.annonc.2025.01.001.

MLA (9th ed.) Citation

Horinouchi, H., et al. "Results from a Phase Ib Study of Telisotuzumab Vedotin in Combination with Osimertinib in Patients with C-Met Protein-overexpressing, EGFR-mutated Locally Advanced/metastatic Non-small-cell Lung Cancer (NSCLC) After Progression on Prior Osimertinib." Annals of Oncology, vol. 36, no. 5, 2025, p. 583, https://doi.org/10.1016/j.annonc.2025.01.001.